跳至主要内容
临床试验/NCT03092518
NCT03092518已完成2 期

Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

National Cancer Institute (NCI)1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2017年6月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
27
试验地点
1
主要终点
Overall Survival (OS)

研究概览

简要总结

Background:

  • Gastric cancer is a common and serious cancer. Standard treatment is chemotherapy drugs. Researchers want to see if a new treatment helps. It is surgical removal of the cancer and heated chemotherapy delivered to the abdominal cavity called Hyperthermic intraperitoneal chemotherapy (HIPEC).

Objective:

  • To test if surgical removal of tumors plus heated intraperitoneal chemotherapy can improve survival in people with gastric cancers.

Eligibility:

  • People ages 18 and older with gastric cancer who can have most tumors surgically removed

Design:

  • Participants will be screened with:
  • Medical history
  • Physical exam
  • Blood, urine, and heart tests
  • Scans
  • Tissue sample from previous surgery
  • Endoscopy with biopsy: A tube with a camera goes through the mouth and into the stomach. It and takes a sample of stomach tissue. Participants may get medicine to make them drowsy.
  • Laparoscopy: Small cuts are made in the abdomen. A thin tube with a light and camera is inserted into the abdomen. Participants sleep through the procedure.

Participants will stay in the hospital. They will have:

  • Surgery to remove as many tumors as possible.
  • HIPEC for 60 minutes: Two thin tubes are put into the abdomen. Two chemotherapy drugs are given through one tube. They are drained out through another at a temperature a few degrees above normal body temperature. Another drug is given in a vein.
  • Recovery for 7-21 days: Participants will have tubes in their stomach and bladder and intravenous (IVs) for a few days. They will get pain medicine, IV fluids, antibiotics, and blood transfusions as needed.
  • Participants will have visits every few months for 3 years, then one a year. Visits include physical exam, blood tests, and scans. They also include dietary assessment and questions.

详细描述

Background:

  • An estimated 24,590 cases of gastric adenocarcinoma are diagnosed annually in the United States (U.S.).
  • The peritoneal surface is a site of metastasis found often at time of diagnosis and is a common (40%) site of recurrence.
  • Laparoscopy with peritoneal lavage and cytopathologic analysis is a staging modality that can identify a subset of patients with microscopic peritoneal metastasis prior to consideration for definitive surgical therapy.
  • Intraperitoneal chemotherapy has been employed in advanced gastric cancers and as an adjuvant with an associated improvement in survival in systematic reviews.

Objectives:

  • Determine the overall survival in patients with cytology-positive gastric cancer treated with Hyperthermic intraperitoneal chemotherapy (HIPEC) and gastrectomy.

Eligibility:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer

Experimental

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy

干预措施: Surgery (Procedure)

Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer

Experimental

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy

干预措施: Cisplatin (Drug)

Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer

Experimental

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy

干预措施: Mitomycin C (Drug)

Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer

Experimental

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy

干预措施: Sodium Thiosulfate (Drug)

Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer

Experimental

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy

干预措施: Tumor Biopsy (Procedure)

Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer

Experimental

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy

干预措施: CT C/A/P (Diagnostic Test)

Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer

Experimental

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy

干预措施: PET-CT (Diagnostic Test)

Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer

Experimental

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy

干预措施: MRI (Diagnostic Test)

Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer

Experimental

Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy

干预措施: EKG (Diagnostic Test)

结局指标

主要结局

Overall Survival (OS)

时间窗: 53.7 months

OS is defined as the median amount of time a participant survives after therapy.

次要结局

  • Intraperitoneal Progression Free Survival (IPFS) at 6 Months, 12 Months and 18 Months(6 months, 12 months and 18 months)
  • Extra-peritoneal Disease-free Survival(48.9 months)
  • Number of Treatment Related Serious and/or Non-serious Adverse Events by Type(Up to 1646 days)

研究者

申办方类型
Nih
责任方
Principal Investigator
主要研究者

Jeremy Davis, M.D.

Investigator

National Cancer Institute (NCI)

研究点 (1)

Loading locations...

相似试验

Heated Intraperitoneal Chemotherapy and Gastrectomy... | 临床试验